Product Description
Amoxicillin is used to treat certain infections caused by bacteria, such as pneumonia; bronchitis (infection of the airway tubes leading to the lungs); and infections of the ears, nose, throat, urinary tract, and skin. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. Amoxicillin is in a class of medications called penicillin-like antibiotics. It works by stopping the growth of bacteria. (Sourced from: https://medlineplus.gov/druginfo/meds/a685001.html)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Skin Ulcer | Duodenal Ulcer | Helicobacter Infections | Respiratory Tract Infections | Urinary Tract Infections | Pharyngitis | Tonsillitis | Helicobacter Infections
Known Adverse Events: Diarrhea | Headache | Hypertension | Abdominal Pain | Dysgeusia | Pain Unspecified | Nasopharyngitis | Pharyngitis | Candidiasis | Candidiasis, Vulvovaginal
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Benin, Canada, China, Colombia, Croatia, France, Germany, Hungary, India, Ireland, Japan, Kenya, Nepal, Netherlands, New Zealand, Pakistan, Portugal, Romania, Saudi Arabia, Spain, United Kingdom, United States
Active Clinical Trial Count: 17
Highest Development Phases
Phase 3: Acute Respiratory Distress Syndrome|COVID-19|Clostridium Infections|Diarrhea|Febrile Neutropenia|Fractures, Open|Helicobacter Infections|Influenza, Human|Intestinal Diseases|Pneumonia|Respiratory Tract Infections|Urinary Tract Infections|Vaginosis, Bacterial
Phase 2: Buruli Ulcer|Diverticulitis|Pyelonephritis
Phase 1: Communicable Diseases|Duodenal Diseases|Duodenal Ulcer|Esophagitis|Short Bowel Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BLMs4BU | P2 |
Recruiting |
Buruli Ulcer |
2026-05-31 |
|
| REMAP-CAP | P3 |
Recruiting |
Pneumonia|Influenza, Human|COVID-19 |
2026-02-01 |
|
| DURATIOM | P3 |
Not yet recruiting |
Fractures, Open |
2026-01-31 |
|
| DIREBIOT | P2 |
Not yet recruiting |
Diverticulitis |
2025-12-31 |